GE Healthcare is seeking approval to independently manufacture Optison, a contrast agent for cardiac imaging. The company has submitted a supplemental new drug application for the agent to U.S. regulators. "While we cannot predict a timeline for regulatory authority approval, we look forward to servicing the U.S. cardiology community directly in 2013," said GE Healthcare's Stephen Lightfoot.

Related Summaries